SCOPUS 정보 검색 플랫폼

Pharmacogenomics

Volumn 5, Issue 3, 2004, Pages 225-228

Personalized cancer therapy - The key to the future

(1) Sikora, Karol a,b

a HAMMERSMITH HOSPITAL (United Kingdom)

b NONE (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; FLUOROURACIL;

BIOTECHNOLOGY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CANCER THERAPY; COST OF ILLNESS; DRUG INDUSTRY; DRUG SAFETY; DRUG TARGETING; EDITORIAL; HUMAN; MEDICAL DECISION MAKING; MEDICAL GENETICS; PATIENT CARE; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 11044233789 PISSN: 14622416 EISSN: None Source Type: Journal
DOI: 10.1517/phgs.5.3.225.29829 Document Type: Editorial

Times cited : (12)

References (10)

1
- 16544377586
- Principles of chemotherapy and drug development
- Price P, Sikora K (Eds), Arnold, London
- Vasey P, Evans J: Principles of chemotherapy and drug development. In: Treatment of Cancer. Price P, Sikora K (Eds), Arnold, London 103-130 (2002).
- (2002) Treatment of Cancer , pp. 103-130
- Vasey, P.¹ Evans, J.²

2
- 0034863637
- Innovative cancer drug targets: Genomics, transcriptomics and clinomics
- Workman P, Clarke P: Innovative cancer drug targets: genomics, transcriptomics and clinomics. Expert Opin. Pharmacother. 2(6), 911-915 (2001).
- (2001) Expert Opin. Pharmacother. , vol.2 , Issue.6 , pp. 911-915
- Workman, P.¹ Clarke, P.²

3
- 0347132559
- Clinical implications of advanced molecular cytogenetics in cancer
- Mundle S, Sokolowa J: Clinical implications of advanced molecular cytogenetics in cancer. Expert Rev. Mol. Diag. 4, 71-81 (2004).
- (2004) Expert Rev. Mol. Diag. , vol.4 , pp. 71-81
- Mundle, S.¹ Sokolowa, J.²

4
- 0036596857
- The impact of pharmacogenetics and pharmacogenomics on drug discovery
- Lindpainter K: The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nat. Rev. Drug Discov. 1, 463-468 (2002).
- (2002) Nat. Rev. Drug Discov. , vol.1 , pp. 463-468
- Lindpainter, K.¹

5
- 0037137586
- Predictive molecular pathology
- Sauter G, Simon R: Predictive molecular pathology. N. Engl. J. Med. 347, 1995-1996 (2002).
- (2002) N. Engl. J. Med. , vol.347 , pp. 1995-1996
- Sauter, G.¹ Simon, R.²

6
- 0037107019
- Surrogate endpoints in cancer drug development
- Sikora K: Surrogate endpoints in cancer drug development. Drug Discov. Today 7, 951-956 (2002).
- (2002) Drug Discov. Today , vol.7 , pp. 951-956
- Sikora, K.¹

7
- 0037027131
- Prostate specific antigen testing for prostate cancer
- Thornton H, Dixon-Woods M: Prostate specific antigen testing for prostate cancer. Br. Med. J. 325, 725-726 (2002).
- (2002) Br. Med. J. , vol.325 , pp. 725-726
- Thornton, H.¹ Dixon-Woods, M.²

8
- 0242361278
- Predictive ability of DNA microarrays for cancer outcomes and correlates: An empirical assessment
- Nizani E, Ionnaidis J: Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 362, 1439-1444 (2003).
- (2003) Lancet , vol.362 , pp. 1439-1444
- Nizani, E.¹ Ionnaidis, J.²

9
- 1542328193
- Diagnostics in cancer drug development
- Sikora K: Diagnostics in cancer drug development. Expert Rev. Mol. Diag. 4, 127-129 (2004).
- (2004) Expert Rev. Mol. Diag. , vol.4 , pp. 127-129
- Sikora, K.¹

10
- 4444383982
- The economics of cancer care
- (In Press)
- Bosanquet N, Sikora K: The economics of cancer care. Lancet Oncol. (2004) (In Press).
- (2004) Lancet Oncol.
- Bosanquet, N.¹ Sikora, K.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.